Effects of Fasudil on Patients with Pulmonary Hypertension Associated with Left Ventricular Heart Failure with Preserved Ejection Fraction: A Prospective Intervention Study

Background. Pulmonary hypertension due to left ventricular heart failure with preserved ejection fraction (PH-HFpEF) is an increasingly medical problem. The aim of the study was to evaluate the clinical efficacy of fasudil on PH-HFpEF elderly patients and to figure out the subtype of PH-HFpEF which...

Full description

Saved in:
Bibliographic Details
Main Authors: Xiang Zhang, Xueming Zhang, Saihua Wang, Jun Luo, Zhihong Zhao, Changzhu Zheng, Jieyan Shen
Format: Article
Language:English
Published: Wiley 2018-01-01
Series:Canadian Respiratory Journal
Online Access:http://dx.doi.org/10.1155/2018/3148259
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832565958568312832
author Xiang Zhang
Xueming Zhang
Saihua Wang
Jun Luo
Zhihong Zhao
Changzhu Zheng
Jieyan Shen
author_facet Xiang Zhang
Xueming Zhang
Saihua Wang
Jun Luo
Zhihong Zhao
Changzhu Zheng
Jieyan Shen
author_sort Xiang Zhang
collection DOAJ
description Background. Pulmonary hypertension due to left ventricular heart failure with preserved ejection fraction (PH-HFpEF) is an increasingly medical problem. The aim of the study was to evaluate the clinical efficacy of fasudil on PH-HFpEF elderly patients and to figure out the subtype of PH-HFpEF which may be the therapeutic object of fasudil. Method. 58 PH-HFpEF elderly patients were enrolled. Patients were diagnosed with passive pulmonary hypertension (PPH) or reactive pulmonary hypertension (RPH) by right heart catheterization and all receiving Rho kinase inhibitor fasudil for 2 weeks. The endpoint includes changes in SpO2, NT-pro BNP, cardiac functional classification, and echocardiography measurements after 2 weeks treatment. Results. The course of disease in the RPH group was longer than the PPH group (p<0.05). Cardiac output was found to be worse in the RPH group than the PPH group (p<0.01). Besides, the RPH group demonstrated a greater transpulmonary pressure gradient (TPG) and pulmonary vascular resistance (PVR) than the PPH group (p<0.01 for both) as well as pulmonary arterial systolic pressure (PASP) and mean pulmonary arterial pressure (mPAP) (p<0.01 for both), which fits the feature of RPH. After treatment of fasudil, in RPH group, PASP significantly decreased (p<0.01) with decreased E/E′ and increased E/A (p<0.05 for both), indicating that pulmonary haemodynamics and cardiac diastolic function were ameliorated, but the measurements in the PPH group had no significant changes. NT-pro BNP and 6 MWD of both groups were improved (p<0.05). The total effective rate of the RPH group was 74.29%, which was higher than 47.83% of the PPH group (p<0.05). Conclusion. The Rho kinase inhibitor fasudil can improve pulmonary and left ventricular haemodynamics in patients with PH-HFpEF. The total effective rate was higher in the RPH group. Fasudil may be a promising targeted drug for the RPH in PH-HFpEF patients. This trial is registered with ChiCTR-INR-16009511.
format Article
id doaj-art-d78e569508984a6eb6bfd7b15cafab2f
institution Kabale University
issn 1198-2241
1916-7245
language English
publishDate 2018-01-01
publisher Wiley
record_format Article
series Canadian Respiratory Journal
spelling doaj-art-d78e569508984a6eb6bfd7b15cafab2f2025-02-03T01:06:13ZengWileyCanadian Respiratory Journal1198-22411916-72452018-01-01201810.1155/2018/31482593148259Effects of Fasudil on Patients with Pulmonary Hypertension Associated with Left Ventricular Heart Failure with Preserved Ejection Fraction: A Prospective Intervention StudyXiang Zhang0Xueming Zhang1Saihua Wang2Jun Luo3Zhihong Zhao4Changzhu Zheng5Jieyan Shen6Shanghai Zhoupu Hospital, Shanghai, ChinaRenji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, ChinaShanghai Zhoupu Hospital, Shanghai, ChinaShanghai Zhoupu Hospital, Shanghai, ChinaShanghai Zhoupu Hospital, Shanghai, ChinaShanghai Zhoupu Hospital, Shanghai, ChinaRenji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, ChinaBackground. Pulmonary hypertension due to left ventricular heart failure with preserved ejection fraction (PH-HFpEF) is an increasingly medical problem. The aim of the study was to evaluate the clinical efficacy of fasudil on PH-HFpEF elderly patients and to figure out the subtype of PH-HFpEF which may be the therapeutic object of fasudil. Method. 58 PH-HFpEF elderly patients were enrolled. Patients were diagnosed with passive pulmonary hypertension (PPH) or reactive pulmonary hypertension (RPH) by right heart catheterization and all receiving Rho kinase inhibitor fasudil for 2 weeks. The endpoint includes changes in SpO2, NT-pro BNP, cardiac functional classification, and echocardiography measurements after 2 weeks treatment. Results. The course of disease in the RPH group was longer than the PPH group (p<0.05). Cardiac output was found to be worse in the RPH group than the PPH group (p<0.01). Besides, the RPH group demonstrated a greater transpulmonary pressure gradient (TPG) and pulmonary vascular resistance (PVR) than the PPH group (p<0.01 for both) as well as pulmonary arterial systolic pressure (PASP) and mean pulmonary arterial pressure (mPAP) (p<0.01 for both), which fits the feature of RPH. After treatment of fasudil, in RPH group, PASP significantly decreased (p<0.01) with decreased E/E′ and increased E/A (p<0.05 for both), indicating that pulmonary haemodynamics and cardiac diastolic function were ameliorated, but the measurements in the PPH group had no significant changes. NT-pro BNP and 6 MWD of both groups were improved (p<0.05). The total effective rate of the RPH group was 74.29%, which was higher than 47.83% of the PPH group (p<0.05). Conclusion. The Rho kinase inhibitor fasudil can improve pulmonary and left ventricular haemodynamics in patients with PH-HFpEF. The total effective rate was higher in the RPH group. Fasudil may be a promising targeted drug for the RPH in PH-HFpEF patients. This trial is registered with ChiCTR-INR-16009511.http://dx.doi.org/10.1155/2018/3148259
spellingShingle Xiang Zhang
Xueming Zhang
Saihua Wang
Jun Luo
Zhihong Zhao
Changzhu Zheng
Jieyan Shen
Effects of Fasudil on Patients with Pulmonary Hypertension Associated with Left Ventricular Heart Failure with Preserved Ejection Fraction: A Prospective Intervention Study
Canadian Respiratory Journal
title Effects of Fasudil on Patients with Pulmonary Hypertension Associated with Left Ventricular Heart Failure with Preserved Ejection Fraction: A Prospective Intervention Study
title_full Effects of Fasudil on Patients with Pulmonary Hypertension Associated with Left Ventricular Heart Failure with Preserved Ejection Fraction: A Prospective Intervention Study
title_fullStr Effects of Fasudil on Patients with Pulmonary Hypertension Associated with Left Ventricular Heart Failure with Preserved Ejection Fraction: A Prospective Intervention Study
title_full_unstemmed Effects of Fasudil on Patients with Pulmonary Hypertension Associated with Left Ventricular Heart Failure with Preserved Ejection Fraction: A Prospective Intervention Study
title_short Effects of Fasudil on Patients with Pulmonary Hypertension Associated with Left Ventricular Heart Failure with Preserved Ejection Fraction: A Prospective Intervention Study
title_sort effects of fasudil on patients with pulmonary hypertension associated with left ventricular heart failure with preserved ejection fraction a prospective intervention study
url http://dx.doi.org/10.1155/2018/3148259
work_keys_str_mv AT xiangzhang effectsoffasudilonpatientswithpulmonaryhypertensionassociatedwithleftventricularheartfailurewithpreservedejectionfractionaprospectiveinterventionstudy
AT xuemingzhang effectsoffasudilonpatientswithpulmonaryhypertensionassociatedwithleftventricularheartfailurewithpreservedejectionfractionaprospectiveinterventionstudy
AT saihuawang effectsoffasudilonpatientswithpulmonaryhypertensionassociatedwithleftventricularheartfailurewithpreservedejectionfractionaprospectiveinterventionstudy
AT junluo effectsoffasudilonpatientswithpulmonaryhypertensionassociatedwithleftventricularheartfailurewithpreservedejectionfractionaprospectiveinterventionstudy
AT zhihongzhao effectsoffasudilonpatientswithpulmonaryhypertensionassociatedwithleftventricularheartfailurewithpreservedejectionfractionaprospectiveinterventionstudy
AT changzhuzheng effectsoffasudilonpatientswithpulmonaryhypertensionassociatedwithleftventricularheartfailurewithpreservedejectionfractionaprospectiveinterventionstudy
AT jieyanshen effectsoffasudilonpatientswithpulmonaryhypertensionassociatedwithleftventricularheartfailurewithpreservedejectionfractionaprospectiveinterventionstudy